Supraventricular tachycardia AHA recommendations for Management of Multifocal Atria Tachycardia: Difference between revisions
Jump to navigation
Jump to search
Aysha Aslam (talk | contribs) (Created page with "__NOTOC__ {{Supraventricular tachycardia}} {{CMG}} {{AE}}{{AA}} ==Overview== ==Management of Multifocal Atria Tachycardia== ==References== {{Reflist|2}}") |
Aysha Aslam (talk | contribs) |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
==Management of Multifocal Atria Tachycardia== | ==Management of Multifocal Atria Tachycardia== | ||
===Acute treatment of Multifocal Atria Tachycardia=== | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
|colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | |||
|- | |||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.'''Intravenous metoprolol or verapamil can be useful for acute treatment in patients with MAT.<nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])'' <nowiki>"</nowiki> | |||
|} | |||
===Management of ongoing Multifocal Atria Tachycardia=== | |||
{|class="wikitable" style="width:80%" | |||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"| [[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.'''Oral verapamil <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B-NR]])'' <nowiki>"</nowiki> or diltiazem <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])'' <nowiki>"</nowiki> is reasonable for ongoing management in patients with recurrent symptomatic MAT<nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence:B-NR, C-LD]])'' <nowiki>"</nowiki> | |||
|- | |||
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''2.'''Metoprolol is reasonable for ongoing management in patients with recurrent symptomatic MAT ( <nowiki>"</nowiki>''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C-LD]])'' <nowiki>"</nowiki> | |||
|- | |||
|} | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 20:04, 25 October 2016
|
Supraventricular tachycardia Microchapters |
|
Differentiating Among the Different Types of Supraventricular Tachycardia |
|---|
|
Differentiating Supraventricular Tachycardia from Ventricular Tachycardia |
|
Diagnosis |
|
Treatment |
|
2015 ACC/AHA Guideline Recommendations |
|
Case Studies |
|
Supraventricular tachycardia AHA recommendations for Management of Multifocal Atria Tachycardia On the Web |
|
American Roentgen Ray Society Images of Supraventricular tachycardia AHA recommendations for Management of Multifocal Atria Tachycardia |
|
Directions to Hospitals Treating Supraventricular tachycardia |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aysha Anwar, M.B.B.S[2]
Overview
Management of Multifocal Atria Tachycardia
Acute treatment of Multifocal Atria Tachycardia
| Class IIa |
| "1.Intravenous metoprolol or verapamil can be useful for acute treatment in patients with MAT."(Level of Evidence: C-LD) " |
Management of ongoing Multifocal Atria Tachycardia
| Class IIa |
| "1.Oral verapamil "(Level of Evidence: B-NR) " or diltiazem "(Level of Evidence: C-LD) " is reasonable for ongoing management in patients with recurrent symptomatic MAT"(Level of Evidence:B-NR, C-LD) " |
| "2.Metoprolol is reasonable for ongoing management in patients with recurrent symptomatic MAT ( "(Level of Evidence: C-LD) " |